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Background: Despite the interest in the impact of overweight and obesity on public
health, little is known about the social and economic impact of being born large for
gestational age or macrosomic. Both conditions are related to maternal obesity and/or
gestational diabetes mellitus (GDM) and associated with increased morbidity for mother
and child in the perinatal period. Poorly controlled diabetes during pregnancy, pre-
pregnancy maternal obesity and/or excessive maternal weight gain during pregnancy
are associated with intermittent periods of fetal exposure to hyperglycemia and
subsequent hyperinsulinemia, leading to increased birth weight (e.g., macrosomia),
body adiposity, and glycogen storage in the liver. Macrosomia is associated with
an increased risk of developing obesity and type 2 diabetes mellitus later in
life.
Objective: Provide insight in the short-term health-economic impact of maternal
overweight, GDM, and related macrosomia. To this end, a health economic framework
was designed. This pilot study also aims to encourage further health technology
assessments, based on country- and population-specific data.
Results: The estimation of the direct health-economic burden of maternal overweight,
GDM and related macrosomia indicates that associated healthcare expenditures are
substantial. The calculation of a budget impact of GDM, based on a conservative
approach of our model, using USA costing data, indicates an annual cost of more than
$1,8 billion without taking into account long-term consequences.
Conclusion: Although overweight and obesity are a recognized concern worldwide,
less attention has been given to the health economic consequences of these conditions
in women of child-bearing age and their offspring. The presented outcomes underline
the need for preventive management strategies and public health interventions on life
style, diet and physical activity. Also, the predisposition in people of Asian ethnicity to
develop diabetes emphasizes the urgent need to collect more country-specific data on
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the incidence of macrosomic births and health outcomes. In addition, it would be of
interest to further explore the long-term health economic consequences of macrosomia
and related risk factors.
Keywords: maternal overweight, gestational diabetes mellitus, macrosomia, health economics, public health
burden
Introduction
The foundations of health throughout life are laid during the
peri-conceptional period, from conception until birth, and after
birth in early childhood. Much attention has been paid to the
long-term consequences of undernutrition and micronutrient
deﬁciencies during the ﬁrst 1000 days, covering the timespan
from conception until the second birthday (Morton, 2006; Black
et al., 2008). The link between compromised nutritional status
of the baby’s mother and low birth weight on one hand, and
impaired health of the child in later life on the other hand
has now been clearly established. The far-reaching relationships
with multiple health-related outcomes aﬀecting human capital
and productivity have been clearly corroborated (Johnson and
Schoeni, 2011).
In contrast, despite the general high interest in the public
health burden of overweight and obesity, far less is known about
the potential clinical and economic consequences of maternal
conditions leading to high birth weight (large for gestational age;
LGA) or macrosomia.
Macrosomia
Macrosomia is deﬁned as an absolute birth weight >4000 g
regardless of gestational age (Boulet et al., 2003; Costa et al.,
2012). The incidence of macrosomia ranges from 12.8 to 37.4%
worldwide (Rodrigues et al., 2000; Kac and Velasquez-Melendez,
2005; de Oliveira et al., 2008). In developed countries, the
prevalence of macrosomia ranges from 5 to 20%; and an increase
of 15–25% has been reported over the last three decades, mainly
driven by an increase in maternal obesity and type 2 diabetes
(T2DM). In addition, the threshold for macrosomia might need
to be reconsidered for Asian countries, where average birth
weight is in general lower compared to European countries and
consequently the cut oﬀ weight for LGA (>95th percentile)
would be lower.
Maternal overweight, excessive gestational weight gain
(GWG) by itself, gestational diabetes mellitus (GDM), deﬁned
as mild to moderate hyperglycemia leading to diabetes ﬁrst
diagnosed during pregnancy which disappears after giving birth,
and elevated fasting plasma glucose levels during pregnancy have
all been reported to be signiﬁcant risk factors for macrosomia (Shi
et al., 2014). In developing countries maternal short statue, high
body mass index (BMI), and T2DM are strong risk factors for
macrosomia (Koyanagi et al., 2013).
Macrosomia is the main cause of (acute) perinatal
complications for both mother and infant. Adverse maternal
outcomes associated with macrosomia include preterm birth,
higher rates of postpartum hemorrhage, as well as increased
risk of cesarean delivery (HAPO Study Cooperative Research
Group et al., 2008; Henriksen, 2008; Jastrow et al., 2010). For
the macrosomic infant, birth trauma is commonly related to
instrumental delivery, e.g., newborns with a birth weight>4000 g
have 9.0 times higher odds of shoulder dystocia, while those with
a birth weight >4500 g have odds that are 39.5 times higher than
normal-weight infants (Robinson et al., 2003). Furthermore,
macrosomic infants are more likely to have low 5-min Apgar
scores, an index of hypoxia (Johnson and Schoeni, 2011). Infants
with very severe macrosomia (birth weight >5000 g) are at
increased risk of neonatal, post-neonatal and infant death
(Boulet et al., 2003). Macrosomia also signiﬁcantly increases the
risk for developing obesity in childhood, and non-communicable
diseases (NCD) later in life (Morton, 2006).
Background
A key component of normal metabolic adaptation to pregnancy
is the development of mild insulin resistance and changes in the
regulation of appetite in the mother, gradually evolving during
gestation (Parsons et al., 1992; Kawai and Kishi, 1999; Clapp,
2006). These normal physiological adaptations serve to shuttle
suﬃcient nutrients to the growing fetus, especially during the
last trimester of pregnancy. Poorly controlled diabetes, maternal
obesity, and excessive maternal weight gain during pregnancy
are associated with intermittent, non-physiological periods of
fetal hyperglycemia, and subsequent hyperinsulinemia from the
start of pregnancy and onward. The resulting maternal insulin
resistance and hormonal responses related to high blood glucose,
such as insulin-like growth factors, and growth hormone, lead to
greater deposition of body fat and glycogen in muscle and liver in
the fetus. The greater and more rapid fetal growth (in particular
of adipose tissue) subsequently results in increased birth weight.
Overweight, Obesity, and Gestational Weight
Gain
Women with either pre-pregnancy obesity and/or excessive
GWG, have a higher risk for developing GDM, pregnancy-
induced hypertension, cesarean delivery, and LGA and
macrosomic infants compared to women with normal pre-
pregnancy BMI and adequate pregnancy weight gain (Li et al.,
2013).
Using a hospital-based delivery database of 18 362 subjects in
the USA, overweight, obese and severely obese women showed
higher risks for LGA, GDM, and preeclampsia in comparison
to their normal-weight counterparts (Bodnar et al., 2010). In
another study, the proportion of LGA infants born to overweight
and obese mothers without GDMwas signiﬁcantly higher than in
their normal-weight counterparts in a retrospective study of 9 835
women in Southern California, USA; 21.6% of LGA infants were
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explained by maternal overweight and obesity (Black et al., 2013).
Similarly, a 13-years study of 292 568 singleton pregnancies in
China (Liu et al., 2012) demonstrated that adverse pregnancy
outcomes, such as hypertensive disorders, cesarean delivery,
macrosomia, and LGA infants, were associated with overweight
mothers, who during pregnancy gained weight beyond current
IOM recommendations (Institute of Medicine/National Research
Council, 2009).
In a study of 366 886 singleton pregnancies from the
Danish Medical Birth Registry from 2004 to 2010, the ratio
between abdominal circumference and birth weight decreased
with increasing maternal BMI, suggesting that maternal obesity
results in a general weight gain of the fetus rather than just
fat accumulation around the abdomen (Tanvig et al., 2013).
Finally, an observational study at ﬁve antenatal centers in Ireland
reported that excessive GWG resulted in higher odds for LGA
and macrosomia, as well as increased odds for gestational
hypertension in women with GDM. The need for treatment with
insulin further increased the odds for LGA and macrosomia
(Egan et al., 2014).
Altogether, these studies emphasize that high pre-pregnancy
BMI and/or high GWG form a substantial risk for macrosomic
birth worldwide. The fact that some studies do not report
increased rates of macrosomia despite the increasing prevalence
of obese pregnancies, may be explained by, for instance, changes
in obstetric practice such as cesarean section before weeks 40 of
pregnancy (Poston et al., 2011).
Gestational Diabetes Mellitus
In women already prone to insulin resistance because of
obesity or (epi) genetic predisposition (Vaag et al., 2014), this
physiological tendency is augmented and can result in the
development of GDM, commonly diagnosed around weeks
20–24 of pregnancy. A study including 35 253 pregnancies
in Australia showed an average incidence of GDM of 5.5%
(n = 1928; Beischer et al., 1991).
GDM has been reported to aﬀect 4–7% of pregnancies in
Caucasian women, while the incidence is consistently higher
(8–15%), and rising rapidly in Asian women (Ferrara et al.,
2004; Rosenberg et al., 2005; Hunsberger et al., 2010). According
to a recent survey, there is a large variation in estimated
GDM prevalence, showing a range from <1 to 28% with data
derived from single or multi-site, national data, and/or estimates
from expert assessments in 47 countries (Jiwani et al., 2012).
Direct comparison between countries is diﬃcult due to diﬀerent
diagnostic strategies and population groups. Many countries
do not perform systematic screening for GDM, and practices
often diverge from guidelines. Interestingly, the hyperglycemia
and pregnancy outcome (HAPO) study results clearly indicate
that relatively mild hyperglycemia was already associated with
a signiﬁcant increase in macrosomia (Zawiejska et al., 2014).
Adoption of the HAPO criteria for GDM diagnosis will likely lead
to higher GDMprevalence compared to current estimates (Jiwani
et al., 2012), although still considerable diﬀerences in incidence
as well as relevance of the diﬀerent hyperglycemia measures were
reported between the participating HAPO centers (Sacks et al.,
2012).
Objective
The primary objective of this study was to design a health
economic framework that will allow a pilot estimation of
the short-term healthcare burden associated with maternal
overweight and/or GDM, in particular as related to fetal
macrosomia. The secondary goal is to lay a basis for fostering
interest in the development of targeted preventive approaches in
an eﬀort to reduce the related total costs. The subject is closely
related to the problem of rising NCD prevalence and the related
disease outcomes, and will be of interest for both developing and
industrialized countries (Henriksen, 2008; Ma and Chan, 2013).
Materials and Methods
A model to map the health economic consequences of GDM,
overweight pregnancies and macrosomia was developed based
on decision analytical techniques, a well-accepted methodology
in the ﬁeld of health-economics (Weinstein and Fineberg, 1980).
To estimate the health economic impact of management of
macrosomia, the short-term consequences of GDM, obesity and
macrosomia were taken into account. Data sources included
published literature, clinical trials, oﬃcial price/tariﬀ lists, if
available, and national population statistics. This study is based
on methodological guidance derived from cost-eﬀectiveness
studies in nutrition economics (Lenoir-Wijnkoop et al., 2011).
Model Design
The health economic impact is calculated, using a decision
tree model constructed in TreeAge Pro 2005/2006, reﬂecting
treatment patterns and outcomes in the management of obesity
during pregnancy, GDM and related delivery of the macrosomic
infant. The present decision tree model is shown in Figure 1.
During the pregnancy the occurrence of GDM and/or obesity
may lead to various complications in mother and child. The
model consists of two sub-models: (1) development of maternal
GDM, (2) maternal obesity, accompanied or not with the
development of GDM.
Delivery after GDM or obesity is the next “health state.”
The delivery may be normal, leading to “normal child” or
“macrosomic” child. Using conventional principles of clinical
decision analysis, expected clinical, and economic outcomes
are determined as a probability-weighted sum of costs and
outcomes further to the initial treatment decisions. As both
mother and child may be subject to various clinical events
and disease progression after delivery, the number of possible
health states is ﬁnite. Therefore the follow-up beyond delivery
was based on a Markov process. An advantage of applying a
Markov process is that it allows long-term modeling of GDM
and obesity for the mother and its complications for both
mother and child (complicated delivery, macrosomia, and related
morbidity).
Study Population
Themodel included a study population of women of childbearing
agewho are overweight or obese prior to pregnancy. Womenwith
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FIGURE 1 | Structure of the model. Reported events are based on literature: ∗ Includes respectively, hypoglycemia, hyperbilirubinemia, prematurity, macrosomia,
brachial plexus injury, shoulder dystocia, respiratory distress, NICU admission; ∗∗ Includes respectively, prematurity, macrosomia, NICU, stillbirth, IUGR; ◦Only
reported for GDM (Michlin); ◦◦Not reported for GDM.
(preexisting) diabetes mellitus, both type I and type II, or related
morbidity before pregnancy were excluded. The model considers
thus a cohort of otherwise healthy women with a probability of
getting pregnant.
Cost Assessment
An analysis can be conducted from the perspective of the society
in a pre-selected study country, while it is also possible to consider
the payer’s perspective only. The choice of the perspective will
depend on the country-speciﬁc health economic guidelines.
The current cost assessment, performed as a pilot, is based
only on short-term costs caused by the management of the
complications as reported in literature, from the national health
care perspective.
Data Sources
Various data sources were considered for developing the
framework in order to maximize its external validity for any
local setting. A narrative review of the scientiﬁc literature from
several electronic databases was conducted to ﬁnd studies
published between 1994 to July 2014 with the following
keywords: birth weight, (rapid) weight gain, growth trajectories,
body composition, overweight, obesity, metabolic health,
cohort, observational studies, Asia, Australia, and Europe.
Only studies published in English were included. Probabilities
of clinical events and utilities are usually accepted as not
country-speciﬁc and are considered to be transferable beyond
their original production location. They can therefore
be derived from international studies, while economic
measures and information on therapeutic choices depend
on a particular region, country or healthcare system (Lampe
et al., 2009).
Incidence
The incidence rate used for our model was 5.5%, derived from
the study outcomes reported by Beischer et al. (1991). This
is a conservative value, taken into account the incidence rates
reported above (Ferrara et al., 2004; Rosenberg et al., 2005;
Hunsberger et al., 2010), and considering the rising risk of
macrosomic pregnancies related to an overall 15–25% increase in
the proportion of women giving birth to large infants worldwide
(Henriksen, 2008).
Complications
Studies reporting the risk of perinatal adverse outcomes for
mother and child in the case of obesity (Galtier-Dereure et al.,
1995; Michlin et al., 2000; Pathi et al., 2006; Salihu et al., 2011),
mild GDM (Landon et al., 2009; Ohno et al., 2011), and total
GDM (Keshavarz et al., 2005; Reece, 2010; Mission et al., 2012)
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TABLE 1 | Complications in mild gestational diabetes mellitus (GDM) and obese mothers.
Mild GDM Source
Outcomes Landon
Neonatal outcomes Hypo-
glycemia
Hyper-
bilirubinemia
Birth weight
>4000
Preterm delivery NICU
admission
Resp. distress Fat mass in g
Intervention (n = 485) 16.30% 9.60% 5.90% 9.40% 9.00% 1.90% 42,700
Control (n = 473) 15.40% 12.90% 14.30% 11.60% 11.60% 2.90% 46,400
Statistical significance NS NS S NS NS NS S
Maternal outcomes Induction
labor
Cesarean
delivery
Shoulder
dystocia
Preeclampsia Preeclampsia OR
gestational
hypertension
Body mass at
delivery
Weight gain
(g)
Intervention (n = 485) 27.30% 26.90% 1.50% 2.50% 8.60% 3130 280
Control (n = 473) 26.80% 33.80% 4.00% 5.50% 13.60% 3230 500
Statistical significance NS S S S S S
Maternal outcomes∗ Preeclampsia Cesarean
delivery
Ohno
Treatment 8.60% 26.90%
No treatment 13.60% 33.80%
Neonatal outcomes∗ Macrosomia Brachial
plexus injury
NICU admission
Treatment 5.90% 6.70% 9.00%
No treatment 14.30% 6.70% 11.6%
Obese mothers
Anemia Insulin-
diabetes
Other
diabetes
Chronic
hypertension
Preeclampsia Eclampsia Salihu
Non-obese
(n = 90,022)
1.18% 0.83% 2.18% 0.28% 2.42% 0.06%
Obese (n = 26,954) 1.31% 3.08% 7.18% 2.23% 5.89% 0.08%
Statistical significance NS S S S S NS
*Statistical significance not reported.
show that not all complications are statistically signiﬁcant. Data
input on obesity is derived from Salihu et al. (2011) because of the
large sample size of obese women (Table 1), whereas for GDM the
data for mild GDM are used (Galtier-Dereure et al., 1995; Pathi
et al., 2006), taking a conservative approach. Mission et al. (2012)
provided a much higher probability for shoulder dystocia, which
TABLE 2 | Treatment GDM – macrosomia.
Risk Comparison Odds ratio Confidence
interval
Source
Macrosomia Treatment GDM
vs. usual care
0.38 0.30–0.49 Horvath
Macrosomia No treatment
GDM vs. control
2.66 1.93–3.67 Langer
Macrosomia Treatment vs.
control
1.13 0.82–1.55 Langer
LGA (large for
gestational age)
No treatment
GDM vs. control
3.28 2.53–3.67 Langer
Treatment GDM
vs. control
1.06 0.81–1.38 Langer
was taken into account for further cost estimations, as well as
additional information provided by Keshavarz et al. (2005) on the
probability of hydramnion and stillbirth (respectively, 0.60 and
0.40%).
Macrosomia Management in GDM
Table 2 shows an overview of data from studies on interventions
related to macrosomia incidence in GDM (Langer et al., 2005;
Horvath et al., 2010).
Herbst (2005) provided data on direct complications related
to macrosomia. These data may be considered in addition to
previously mentioned data. Using decision analysis techniques,
the authors compared three strategies for an infant with an
estimated fetal weight of 4500 g: labor induction, elective cesarean
delivery, and expectant treatment (Table 3).
Mortality outcomes were based on the study by Mitanchez
(2010) who evaluated the risks of perinatal complications in
infants born to mothers with treated or untreated GDM,
including also risk of death.
Most of the costing data were derived from the studies by
Herbst (2005), Ohno et al. (2011). In case of lack of information
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TABLE 3 | Complications macrosomia.
Fetal macrosomia Cesarean delivery
Elective induction 35%
Expectant mgt 33%
Shoulder dystocia
Elective cesarean delivery 0.1%
Elective induction
Ceasarean delivery 0.3%
Vaginal delivery 14.5%
Expectant management
Ceasarean delivery 0.3%
Vaginal delivery 3%
Plexus injury 18%
Permanent injury 6.7%
on direct data, the costs were based on treatment practice derived
from guidelines or assumptions based on similarities in treatment
(Table 4). Maternal short-term costs are related to cesarean
section, pre-eclampsia, or gestational hypertension, induction of
labor, maternal death. In this model we assume that in case of
normal pregnancy and vaginal delivery, there is a routine cost
of $ 7 790 (Ohno et al., 2011). This assumption is, however,
based on the 2011 situation in the USA only, and outcomes may
be considerably diﬀerent in case speciﬁc costing data of other
countries or at other time points would be used. Because of
the lack of costing data from other countries, we performed an
extreme sensitivity analysis on the costs by varying ±20%.
TABLE 4 | Costing data.
Cost item Cost ($) Cost item Cost ($)
Child_brachplexus 1,757 Mother_anemia 0
Child_hyperbili 2,006 Mother_bodymass 0
Child_hypoglycemia 2,419 Mother_cesarean 4,189
Comp_child_IUFD 82,361 Mother_episiotomy 5,165
Mp_child_IUGR 15,065 Mother_gdm 1,786
Child_macrosomia 4,014 Mother_gest 1,786
Child_NICU 15,065 Mother_gesthyper 1,786
Child_overweight 4,014 Mother_hydramnion 0
Child_premature 3,376 Mother_hypertension 1,786
Child_pretermdelivery 3,376 Mother_induction 5,165
Child_resp_distress 3,376 Mother_PIH 19,184
Child_shoulder 1,757 Mother_pre eclampsia 19,184
Mother_PROM 5,165
Mother_shoulder 950
Mother_still birth 0
Mother_weight gain 0
Assumption routine cost normal pregnancy and vaginal delivery 7,790
Results
The base case analysis gives the results for the period including
pregnancy and delivery only, without including costs of diagnosis
and management of GDM, nor of complications beyond the
obstetric period or consequences for mother and child on the
longer term.
The average of total additional costs for overweight is $ 18 290
per pregnancy/delivery, which consists of average costs for the
mother ($ 13 047), and average costs for the child ($ 5 243).
The average of total additional costs for GDM is $ 15 593
per pregnancy/delivery, which consists of the average costs
for delivery and complications for the mother ($ 11 794)
and the average direct costs for neonatal complications in the
macrosomic child ($ 3 799; Table 5).
TABLE 5 | Base case analysis.
Mother Child Total
Period Pregnancy and delivery
Normal $7,790 $0 $7,790
GDM $11,794 $3,799 $15,593
Overweight $13,047 $5,243 $18,290
Example of a Budget Impact Calculation
The translation of costs per case (pregnancy and delivery only)
to national level, based on pregnancy rate and the incidence of
GDM, leads to the budget impact. To illustrate this, the budget
impact of GDM for the USA was calculated, since most of the
costing data available are provided by USA studies. The national
annual number of pregnancies is 13.68 per 1000 for a population
of 313 847 500 (Indexmundi, 2014; www.indexmundi.com). In
case of a GDM incidence rate of 5.5% (Zawiejska et al., 2014),
this represents an annual number of GDM cases of 236 139 in the
US. With a cost diﬀerence between normal pregnancy/delivery
TABLE 6 | Sensitivity analyses.
Per case BIA
Base case $7,803 $1,842,525,634
Incidence
−20% $7,803 $1,474,020,507
20% $7,803 $2,211,030,761
Cost complications
−20% $4,684 $1,106,116,165
20% $10,921 $2,578,935,103
Cost normal pregnancy
−20% $6,242 $9,363
20% $1,474,020,507 $2,211,030,761
Cost complications baby
−20% $5,444 $10,161
20% $1,285,536,028 $2,399,515,240
Cost complications mother
$7,043 $8,563
$1,663,105,770 $2,021,945,498
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and complicated delivery due to GDM of $7 803 ($15 593 – $7
790), this leads to an annual budget impact of more than $1.8
billion, according to the short term conservative approach taken
in our model. Although these outcomes cannot be extrapolated
to other countries because of diﬀerences in costs as well as in
the organization of national health structures, the principle of
calculation remains similar for any part of the world, and will be
of use as soon as reliable information becomes available.
Table 6 shows an overview of the sensitivity analyses. Because
of lack of statistical distributions, the sensitivity analyses were
conducted by varying the parameters ±20%. The outcomes show
that in all sensitivity analyses the economic impact remains
substantial.
Discussion
The current model proposes to assess the health economic
consequences of macrosomia. Based on international
epidemiological and US population costing data, it was
shown that the budget impact related to short term obstetric
complications for both mother and child is considerable. The
presented model oﬀers a ﬁrst approach for further health
technology assessments in diﬀerent parts of the world and can
be used with country speciﬁc data to evaluate cost-eﬀectiveness
of proposed preventive interventions to reduce the current
and future public health consequences of macrosomia. It is
anticipated that the reported pilot assessment using available US
costing data provides a conservative picture of the true health
economic impact of macrosomic births, given the reported
increase in maternal overweight and obesity, not only in
developed but also in developing countries. The recent debate
on diagnostic criteria for GDM stirred by the linear relationship
between maternal hyperglycemia and fetal outcomes adds
further fuel to this assumption (Jiwani et al., 2012; Sacks et al.,
2012).
Relevance and Applicability of this
Framework
Maternal BMI, nutritional status and dietary intake are the main
determinants of fetal growth as well as the occurrence of maternal
hyperglycemia. The latter may result in GDM, deﬁned as diabetes
ﬁrst diagnosed during pregnancy, and is particularly prevalent –
and increasing rapidly– in the Asian regions (Hunsberger et al.,
2010). Ethnic diﬀerences play a pivotal role in the risk for fetal
macrosomia. Worldwide, the rising epidemics of overweight in
girls and women of child-bearing age do not bode well and calls
for preventive strategies (Mulla et al., 2010).
A limitation of this modeling approach lies in the lack of
randomized trial evidence on targeted lifestyle interventions in
pregnancy and their eﬀect on birth outcomes (Balaji et al., 2014;
Briley et al., 2014). However, as maternal overweight, excessive
GWG by itself, GDM, and elevated fasting plasma glucose levels
during pregnancy have all been reported to be signiﬁcant risk
factors for macrosomia (Liu et al., 2012; Black et al., 2013; Li
et al., 2013; Shi et al., 2014), it seems reasonable to assume that
a reduction of GDM (severity) and obese pregnancies would
lead to fewer complications and thus decrease the related health
care costs. Another limitation of the presented framework is its
restriction to short-term costs only. More and more evidence
is emerging on the increased long-term risks for macrosomic
babies to develop future health concerns, including metabolic
syndrome, diabetes, and cancer. Besides the further increase of
related health care expenditures, this also raises the question of
the impact on the next generations (Catalano, 2003; Roseboom
andWatson, 2012), which argues in favor of implementing health
strategies that may contribute to prevent a vicious circle of
NCD.
Dietary management and exercise are potentially eﬀective
interventions to prevent excessive weight gain and GDM if
measures are established before or in the early stages of pregnancy
(Thangaratinam et al., 2012). Evidence from observational
studies and clinical trials indicates that dietary energy intake and
the source of energy inﬂuences glucose metabolism and insulin
responses (Hu et al., 2001; Galgani et al., 2008). High fat diets,
likely to be unbalanced in their macronutrient composition, have
been demonstrated to increase the risk for GDM recurrence
in future pregnancies (Moses et al., 1997). An evaluation of
pregnancy management in women with GDM or gestational
mild hyperglycemia in France demonstrated that there were
no LGA babies in women whose carbohydrate intake was at
least 210 g/day (Romon et al., 2001) indicating the signiﬁcance
of suﬃcient carbohydrate intake during pregnancy. The study
suggested that nutrition counseling should be directed at an
adequate carbohydrate intake of 250 g/day, while maintaining
a low fat diet to limit the total energy intake. Indeed, higher
consumption of saturated fat and trans fat as a percentage of
total energy intake, added sugar and lower intake of vegetables
and fruit ﬁber during the second trimester of pregnancy were
associated with greater risk for glucose intolerance during
the last trimester of pregnancy (Ley et al., 2011). A similar
study suggests an association between saturated fat and sugar
intake during the second trimester with not only birth weight,
but also body weight, and adiposity in the oﬀspring at
5 years of age (Murrin et al., 2013). A ‘high’ glycemic diet
resulting in elevated postprandial glucose levels compared to
a ‘low’ glycemic diet may signiﬁcantly increase birth weight
in healthy pregnant women (McGowan and McAuliﬀe, 2010;
Tzanetakou et al., 2011). Although these studies suggest that a
balanced macronutrient intake as well as carbohydrate quality
play a crucial role in dietary management of GDM, health
economic costs assessment of dietary approaches to date is
limited.
Long-Term Risk of Gestational Diabetes
Mellitus
The current pilot analysis focusses only on costs related
to perinatal complications of macrosomic birth. Several
studies on the association between GDM and long-term
risk of diabetes mellitus show that women with GDM
also have a greater risk of developing diabetes in the
future compared to pregnant women with a normal
glucose tolerance (Bellamy et al., 2009; Jiwani et al.,
2012).
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A review by Henry and Beischer (1991) provides similar
results. Using life table techniques, 17 years after the initial
diagnosis of GDM, 40% of women were diabetic compared with
10% in a matched control group of women who had normal
glucose tolerance in pregnancy. The incidence of diabetes was
higher among women who were older, more obese, of greater
parity, and with more severe degrees of glucose intolerance
during pregnancy. Diabetes also occurred more commonly
among women who had a ﬁrst-degree relative who was diabetic,
in women born in Mediterranean and East Asian countries,
and in those who had GDM in two or more pregnancies.
Despite diﬀering testing techniques and varying criteria for the
diagnosis of GDM, follow-up studies from across the world
consistently showed a higher rate of subsequent diabetes among
GDM mothers, associated with increased morbidity, and a
higher mortality rate. Costs associated with the health of the
mother in later years were not considered in the current model
and recent epidemiologic data suggest that the real costs of
macrosomic birth are considerable higher than presented in this
manuscript.
Long Term Risks of Macrosomia
Fetal macrosomia is a risk factor for the development of obesity in
childhood. In the European cohort IDEFICS, children who were
macrosomic at birth showed signiﬁcantly higher actual values
of BMI, waist circumference, and sum of skin fold thickness
(Sparano et al., 2013).
A recent prospective study, conducted in China, examined the
risk factors and long-term health consequences of macrosomia
(Gu et al., 2012). Using a population sample of 21 315 mother-
child pairs, the children were prospectively followed and assessed
for obesity 7 years after birth. Macrosomic infants showed
an increased susceptibility to develop childhood overweight
and/or obesity. Obesity among children is a signiﬁcant risk
factor for the development of insulin resistance, and the
degree of obesity is correlated with the degree of insulin
resistance (Arslanian and Suprasongsin, 1996; Young-Hyman
et al., 2001). A recent literature review indicates an extra
lifetime medical cost of $19,000 for the obese child compared
to a normal weight child, in the USA. To put this into
perspective, if multiplied with the number of obese 10-year-
olds today this yields a total direct medical cost of obesity
of roughly $14 billion for this age alone (Finkelstein et al.,
2014).
To investigate the relationship between birth weight and
later development of GDM, a retrospective study on the
medical records of 388 women from Malta, diagnosed for
GDM (Savona-Ventura and Chircop, 2003) demonstrated
that high birth weight is an important correlate for the
subsequent development of GDM in later life. This study
further supports the notion that the intrauterine inﬂuences
on pancreatic development and peripheral response to
insulin contribute to the development of adult-onset of
T2DM.
Boney examined the development of metabolic syndrome
among LGA and appropriate-for-gestational age children (Boney
et al., 2005). They observed that obesity among 11-years-old
children was a strong predictor for insulin resistance, and the
combination of LGA status and a mother with GDM might
increase this risk. They also reported that LGA oﬀspring of
diabetic mothers were at signiﬁcant risk of developing metabolic
syndrome in childhood.
Again, costs associated with the health of the oﬀspring in
later years were not considered in the current model and the
above mentioned observations further support the notion that
the real costs of macrosomic birth are considerably higher than
the outcomes presented in this pilot analysis.
Conclusion
The health economic decision tree as reported in this paper,
allows mapping the short-term care burden and public health
impact of complications resulting from GDM and overweight
pregnancies. This model gives an impulse for further assessment
of the cost-eﬀectiveness of preventive interventions. In addition,
as the incidence of macrosomia and related risk-factors will
be a key driver for future health care costs, exploration of
the most appropriate data sources and assumptions, as well as
additional data obtained from longitudinal studies and other
epidemiologic recordings, are required to evaluate the long-term
consequences.
The current budget impact analysis, using available
USA data and on short term costs only, shows that the
annual budget impact of GDM and pregnancy overweight
resulting in macrosomic birth can be substantial, thus
emphasizing the importance of avoiding these adverse health
outcomes.
The reported diﬀerences on GDM incidence, obesity or
the combination thereof, as well as the predisposition in
people of Asian ethnicity to develop diabetes and the high
proportion of undiagnosed diabetic conditions in this part
of the world, stresses the need to collect more country-
speciﬁc data for improving the assessments of the health
economic burden of macrosomic birth and of its later
consequences.
The diﬃculties to change lifestyle and dietary behavior
are generally recognized, however, the (pre) pregnancy period
oﬀers a window of opportunity for healthcare monitoring and
nutritional and lifestyle interventions in the receptive population
of future parents. Well-targeted educational programs on lifestyle
and food behavior during (pre) pregnancy are likely to improve
adverse birth outcomes related to macrosomia. On the long run,
this might represent a valuable contribution to the global eﬀorts
in the ﬁght against NCD.
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